https://www.selleckchem.com/pr....oducts/liproxstatin-
307, 95% CI 0.156-0.604, P 0.001) and CV mortality (HR 0.266, 95% CI 0.095-0.748, P 0.012) in diabetics (P 0.512). In contrast, successful CTO revascularization didn't improve outcomes in non-diabetics (all P 0.05). In multivariate cox regression analysis, successful CTO revascularization remained an independent predictor for 3-years survival in diabetic subgroup (HR 0.289, 95% CI 0.125-0.667, P 0.004). The multivariate analysis result was similar after propensity score matching (all-cause mortality, HR 0.348, 95% CI 0.142-0
Like
Comment
Share
